Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia
Tonix Pharmaceuticals (Nasdaq: TNXP) has launched the "Move Fibro Forward" campaign through its commercial subsidiary, Tonix Medicines, Inc. The initiative aims to raise awareness and provide support for individuals affected by fibromyalgia, a condition that has not seen new FDA-approved treatments in over 15 years.
The campaign represents Tonix's commitment to the fibromyalgia community, focusing on validating patient experiences and providing educational resources. The initiative is supported by the Fibromyalgia Association, emphasizing the importance of visibility and support for those affected by this debilitating condition.
Tonix Pharmaceuticals (Nasdaq: TNXP) ha lanciato la campagna "Move Fibro Forward" attraverso la sua filiale commerciale, Tonix Medicines, Inc. L'iniziativa mira a sensibilizzare e offrire supporto alle persone affette da fibromialgia, una condizione per la quale non sono stati approvati nuovi trattamenti dalla FDA da oltre 15 anni.
La campagna rappresenta l'impegno di Tonix verso la comunità della fibromialgia, concentrandosi sulla convalida delle esperienze dei pazienti e sull'offerta di risorse educative. L'iniziativa è supportata dalla Fibromyalgia Association, sottolineando l'importanza della visibilità e del sostegno per chi convive con questa condizione debilitante.
Tonix Pharmaceuticals (Nasdaq: TNXP) ha lanzado la campaña "Move Fibro Forward" a través de su subsidiaria comercial, Tonix Medicines, Inc. La iniciativa busca crear conciencia y brindar apoyo a las personas afectadas por la fibromialgia, una condición que no ha tenido nuevos tratamientos aprobados por la FDA en más de 15 años.
La campaña representa el compromiso de Tonix con la comunidad de fibromialgia, enfocándose en validar las experiencias de los pacientes y ofrecer recursos educativos. La iniciativa cuenta con el respaldo de la Fibromyalgia Association, destacando la importancia de la visibilidad y el apoyo para quienes padecen esta condición debilitante.
Tonix Pharmaceuticals (나스닥: TNXP)는 상업 자회사인 Tonix Medicines, Inc.를 통해 "Move Fibro Forward" 캠페인을 시작했습니다. 이 이니셔티브는 15년 넘게 FDA 승인을 받은 새로운 치료제가 없는 섬유근육통 환자들을 위한 인식 제고와 지원 제공을 목표로 합니다.
이 캠페인은 섬유근육통 커뮤니티에 대한 Tonix의 헌신을 나타내며, 환자 경험의 인정과 교육 자료 제공에 중점을 둡니다. 이 이니셔티브는 Fibromyalgia Association의 지원을 받아, 이 쇠약해지는 질환에 영향을 받는 이들의 가시성과 지원의 중요성을 강조합니다.
Tonix Pharmaceuticals (Nasdaq : TNXP) a lancé la campagne "Move Fibro Forward" via sa filiale commerciale, Tonix Medicines, Inc. Cette initiative vise à sensibiliser et à soutenir les personnes atteintes de fibromyalgie, une maladie pour laquelle aucun nouveau traitement approuvé par la FDA n’a été mis sur le marché depuis plus de 15 ans.
La campagne illustre l’engagement de Tonix envers la communauté de la fibromyalgie, en mettant l’accent sur la validation des expériences des patients et la fourniture de ressources éducatives. Cette initiative est soutenue par la Fibromyalgia Association, soulignant l’importance de la visibilité et du soutien pour les personnes touchées par cette maladie invalidante.
Tonix Pharmaceuticals (Nasdaq: TNXP) hat die Kampagne "Move Fibro Forward" über seine Vertriebsgesellschaft Tonix Medicines, Inc. gestartet. Die Initiative zielt darauf ab, das Bewusstsein für Fibromyalgie zu erhöhen und Betroffene zu unterstützen – eine Erkrankung, für die seit über 15 Jahren keine neuen von der FDA zugelassenen Behandlungen verfügbar sind.
Die Kampagne zeigt Tonix’ Engagement für die Fibromyalgie-Community, indem sie die Erfahrungen der Patienten anerkennt und Bildungsressourcen bereitstellt. Die Initiative wird von der Fibromyalgia Association unterstützt und unterstreicht die Bedeutung von Sichtbarkeit und Unterstützung für Menschen, die unter dieser schwächenden Erkrankung leiden.
- None.
- None.
CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercial subsidiary, launched the Move Fibro Forward campaign to bring awareness and support to individuals impacted by fibromyalgia, a debilitating condition with no new FDA-approved treatments in over 15 years.
“Millions of individuals impacted by fibromyalgia have suffered in silence for far too long,” said Thomas Englese, President of Tonix Medicines, Inc. “We believe that demonstrating our knowledge of, and compassion for, their condition and validation of their experience is an important step toward meaningful progress. This campaign is a reflection of our commitment to the community—both today and in the future.”
“Fibromyalgia can make you feel invisible,” said Sharon Waldrop, a person with lived experience and Founder of the Fibromyalgia Association. “Initiatives like Move Fibro Forward help shine a light on our experiences and encourage individuals impacted by fibromyalgia to seek education and resources.”
For more information about the campaign, visit www.movefibroforward.com.
About Fibromyalgia
Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., approximately
Tonix Pharmaceuticals Holding Corp.
Tonix is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, and infectious diseases. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, Inc. our wholly owned commercial subsidiary, markets treatments for acute migraine.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599
Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com
Media Contact
Ray Jordan
Putnam Insights
ray@putnaminsights.com
FAQ
What is the Move Fibro Forward campaign launched by Tonix Pharmaceuticals (TNXP)?
How long has it been since the last FDA-approved treatment for fibromyalgia?
Who is supporting Tonix Pharmaceuticals' (TNXP) fibromyalgia awareness campaign?
Where can people find information about Tonix Pharmaceuticals' (TNXP) Move Fibro Forward campaign?
